Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containi...
Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy
About this item
Full title
Author / Creator
Socié, Gérard , Barba, Pere , Barlev, Arie , Sanz, Jaime , García-Cadenas, Irene , Chevallier, Patrice , Fagioli, Franca , Guzman-Becerra, Norma , Kumar, Deepali , Ljungman, Per , Pigneux, Arnaud , Sadetsky, Natalia , Yáñez San Segundo, Lucrecia , Shadman, Mazyar , Storek, Jan , Thirumalai, Dhanalakshmi , Xing, Baodong and Mohty, Mohamad
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Epstein–Barr virus-positive (EBV
+
) post-transplant lymphoproliferative disease (PTLD) is an ultra-rare and aggressive condition that may occur following allogeneic hematopoietic cell transplant (HCT) due to immunosuppression. Approximately half of EBV
+
PTLD cases are relapsed or refractory (R/R) to initial rituximab-containing therap...
Alternative Titles
Full title
Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy
Authors, Artists and Contributors
Author / Creator
Barba, Pere
Barlev, Arie
Sanz, Jaime
García-Cadenas, Irene
Chevallier, Patrice
Fagioli, Franca
Guzman-Becerra, Norma
Kumar, Deepali
Ljungman, Per
Pigneux, Arnaud
Sadetsky, Natalia
Yáñez San Segundo, Lucrecia
Shadman, Mazyar
Storek, Jan
Thirumalai, Dhanalakshmi
Xing, Baodong
Mohty, Mohamad
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_swepub_ki_se_825768
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_825768
Other Identifiers
ISSN
0268-3369
E-ISSN
1476-5365
DOI
10.1038/s41409-023-02127-9
